The overall role of the Administrative Core is to oversee the operation of the CF Center. The Administrative Core coordinates Core functions. Center-related meetings, enrichment, training and communications that all require an infrastructure with centralized operations to function well. CF Center research is the beneficiary of this coordination. Dr. Mitchell Drumm will direct the administrative duties, assisted by Ms. Connie May. The responsibilities will include decisions regarding allocations of Center resources (core availability, pilot and feasibility allocation, etc.), implementation of an effective enrichment program, development and maintenance of a CF Center-specific website and to preside over the Center executive committee.
The aims of the Administrative Core are: 1) To coordinate activities of the Center 2) To allocate resources of the Center 3) To provide administrative and clerical assistance for Center-related activities 4) To provide pilot and feasibility opportunities to young investigators embarking on CF-related research, or more senior investigators entering CF research or proposing to change direction in CF. 5) To plan and execute an enrichment program consisting of seminars by local and guest faculty lecturers, as well as by trainees in the Center
The scope and size of our Center requires an infrastructure to coordinate activities and to oversee that the basic and clinical research projects are designed and conducted in a manner that results in meaningful research and contributes to the overall mission of the Center.
|Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563|
|Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42|
|VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9|
|VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790|
|Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87|
|Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21|
|VanDevanter, Donald R; Pasta, David J; Konstan, Michael W (2015) Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 14:763-9|
|Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2015) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros :|
|Powers, Scott W; Stark, Lori J; Chamberlin, Leigh A et al. (2015) Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trial. JAMA Pediatr 169:e150636|
|Sagel, Scott D; Thompson, Valeria; Chmiel, James F et al. (2015) Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. Ann Am Thorac Soc 12:708-17|
Showing the most recent 10 out of 417 publications